Elanco Animal Health Incorporated Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
Elanco Animal Health Incorporated (ELAN) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $51.00 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2026-02-24
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $51.00M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $42.00M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $37.00M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $32.00M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits as first filed |
|---|---|---|
| 2025-12-31 | $51.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $42.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $37.00M 10-K · filed 2025-02-25 | |
| 2022-12-31 | $32.00M 10-K · filed 2024-02-26 | |
| 2021-12-31 | $58.00M 10-K · filed 2023-03-01 | |
| 2020-12-31 | $69.00M 10-K · filed 2022-02-28 | $68.50M 10-K · filed 2021-03-01 |
| 2019-12-31 | $25.30M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $32.20M 10-K · filed 2020-02-28 | |
| 2017-12-31 | $34.80M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |